Preetesh Jain MD, DM, PhD

Assistant Professor, Department of Lymphoma and Myeloma. University of Texas MD Anderson Cancer Center, Houston Texas, United States

[Preetesh Jain MD, DM, PhD @JainP_MCL]

@iamsrk All the best.. me and my eight year old son are your big fans.. from Houston with love.. he wishes to meet you someday in Mannat… regards

[Preetesh Jain MD, DM, PhD @JainP_MCL]

@narendramodi He was the greatest freedom fighter, and the main reason behind independence. I want to sincerely thank your govt for recognizing him after so many years, but request to completely disclose the files related to his death and give him the recognition which this nation owes him.

[Preetesh Jain MD, DM, PhD @JainP_MCL]

@NitinJainMD @GCC_Cortes @GACancerCenter @vamkota Very nice to see you Dr Cortes in Himalayas..

[Preetesh Jain MD, DM, PhD @JainP_MCL]

@NitinJainMD @GomezDLeonMD @AlmanzaLeukMD @GCC_Cortes @MDmasarova @SharonCastelli2 @Anand_88_Patel @KMirza @doctorpemm @FadiHaddad_MD @jayastuMD @BldCancerDoc @VivekSubbiah Was a great pleasure getting to meet everyone and a great opportunity…

[Preetesh Jain MD, DM, PhD @JainP_MCL]

@StratNewsGlobal @nitingokhale @adgpi @SuryaGangadha13 @s_jkr @amitabhprevi @SpokespersonMoD I love the conversation and the discussion about this. However, I want to know what will be the security implications of doing this discussion in such a public domain have you ever thought about it Mr. Ghokale?

[Preetesh Jain MD, DM, PhD @JainP_MCL]

@jaymbsanycgmai1 Very true.. loyalty can’t be one way… if that is one way then it becomes exploitation..

[Preetesh Jain MD, DM, PhD @JainP_MCL]

@iamsrk Best of your performances. Reminds me of how I was and until now.

[Ash Alizadeh, MD/PhD 🇺🇸 @AshAlizadeh]

Wow. Humbled & honored to have our study of #cfDNA #liquidbiopsy for #CARTcell #celltherapy of #lymsm called a "compelling" & "tour-de-force" w "vivid prognostic insights" by @NatRevClinOncol @MarcelaMaus @Mark_Leick https://t.co/usnfHkV5UF https://t.co/AP4f7XyhBE @Cancer_Cell

[Preetesh Jain MD, DM, PhD @JainP_MCL]

@AshAlizadeh @NatRevClinOncol @MarcelaMaus @Mark_Leick @Cancer_Cell Truly amazing work on CART resistance in DLBCL

[Preetesh Jain MD, DM, PhD @JainP_MCL]

@AllGasNoBrake13 @jaymbsanycgmai1 Many congratulations

[Preetesh Jain MD, DM, PhD @JainP_MCL]

@narendramodi @DrSJaishankar One of the best thing which could happen to india is Dr Jaishankar.. happy birthday sir and have a long healthy life ahead

[Preetesh Jain MD, DM, PhD @JainP_MCL]

@VincentRK Really lucky to have a mentor who had nothing left to prove but sadly in academia the “greed” seems to be everlasting in many instances even if you have “nothing left to prove” and don’t allow to promote, rather use to their advantage.

[Preetesh Jain MD, DM, PhD @JainP_MCL]

@HadidiSamer Absolutely true. It’s highly political mixed with high degree of jealousy. Instead of supporting they would pull one down. This is prevalent even if people are well established..academics largely is that way.. but you know what - everyone will have to answer to almighty!!!

[Preetesh Jain MD, DM, PhD @JainP_MCL]

@DocHutchings @glimelius @DrRaulCordoba @DavidSteensma @tobyeyre82 @graham74GC In most cases we are able to get it approved based largely on our frontline ibrutinib based data…

[Preetesh Jain MD, DM, PhD @JainP_MCL]

@graham74GC @glimelius @DrRaulCordoba @DocHutchings @DavidSteensma @tobyeyre82 I vs AI results with longer follow up would be the key. Need to get clarity on CR rates and second cancers. In our window-1 study the CR to ibrutinib rituximab alone was about 80%. We do IR maintenance post induction in high risk patients. Also the % of high risk patients was <20

[Preetesh Jain MD, DM, PhD @JainP_MCL]

@jaymbsanycgmai1 @MDAndersonNews @michaelwangmd Super work and congratulations to @michaelwangmd and our MCL team for team work and wonderful enrollment…

[Maria Badillo, MSN RN OCN CCRP @jaymbsanycgmai1]

Amazing news! We are so happy to participate in this game changing trial for elderly MCL patients. @MDAndersonNews @michaelwangmd @JainP_MCL

[Preetesh Jain MD, DM, PhD @JainP_MCL]

@frbertoni @SAKK_ch Congratulations well deserved

[Preetesh Jain MD, DM, PhD @JainP_MCL]

Congratulations @michaelwangmd @jaymbsanycgmai1 @MDAndersonNews

[Preetesh Jain MD, DM, PhD @JainP_MCL]

Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial https://t.co/GTptA9zVUH